DBV Technologies (DBVT) news

DBV Technologies SA shares up 6% after co submits FDA BLA for Viaskin peanut patch in children ages 4-7

DBV Technologies SA (EPA:DBV) reported a 6% increase in its share price following the company’s submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its Viaskin Peanut patch for children aged 4 to 7 years. The submission marks a significant…

DBV Technologies SA: Has requested priority review of BLA

DBV Technologies S.A. (Euronext: DBV – Nasdaq: DBVT) has indicated that its Biologics License Application (BLA) for the VIASKIN® Peanut Patch may be eligible for priority review by the FDA . The company plans to submit the BLA in the first half of 2026, following the successful completion of the…

DBV Technologies: Portzamparc cuts target price to EUR 4.41 from EUR 4.90; rating 'accumulate'

DBV Technologies announces sale of approximately $50 million of ADSs through its at-the-market (ATM) program on Nasdaq

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT), a clinical-stage biopharmaceutical company, has announced the sale of approximately $50 million of American Depositary Shares (ADSs) through its at-the-market (ATM) program on Nasdaq. The ADSs were issued under the…

DBV Technologies SA files for mixed shelf; size not disclosed - SEC filing

DBV Technologies SA has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for a mixed shelf offering, according to a recent SEC filing [1]. A mixed shelf offering allows a company to register multiple types of securities, including common stock, preferred shares,…